Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 26, 2020
In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN...
-
Nov 19, 2020
Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data Veltassa® will benefit from Fresenius Kabi’s...
Nov 19, 2020- Reduction in number of attacks is leading factor when evaluating prophylactic therapyKING OF PRUSSIA, Pa. 19 Nov 2020 CSL Behring, a global biotherapeutics leader, today announced survey results showing that a vast majority of HAE patients (94%) say it’s important their...
-
Nov 16, 2020
16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...
-
Nov 16, 2020- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia
KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. 16 Nov 2020 Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting...
-
Nov 13, 2020
Ferinject® significantly reduced the incidence of heart failure hospitalizations in patients with iron deficiency after acute heart failure Results of the AFFIRM-AHF trial support the use of...
-
Nov 10, 2020Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
KING OF PRUSSIA, Pa. 10 Nov 2020 Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA)...
-
Nov 9, 2020
Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a...
-
Nov 8, 2020
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Nov 3, 2020
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal phase-III ADVOCATE trial of avacopan St...
-
Nov 2, 2020• Both US and European regulators grant special designation
KING OF PRUSSIA, Pa. 02 Nov 2020 Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from...
-
Oct 29, 2020
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...
-
Oct 29, 2020- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
KING OF PRUSSIA, Pa. 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited (parent company of CSL Behring) to its World’s Best Employers 2020 list. It is the fourth year...
-
Oct 20, 2020
Vifor Pharma secures US commercial rights for i.v. Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with Cara Cara...
-
Oct 20, 2020• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19
MELBOURNE, AU and KING OF PRUSSIA, PA 20 Oct 2020 In its annual R&D briefing to investors today, CSL Limited (ASX:CSL; USOTC:CSLLY) demonstrated how the company is advancing a novel research...
-
Oct 15, 2020
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health...
-
Oct 14, 2020
The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...
-
Oct 8, 2020
October 8, 2020, Melbourne — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the...
-
Oct 8, 2020• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
Osaka, JAPAN and King of Prussia, Pa., USA – October 8,2020 – The CoVIg-19 Plasma Alliance, an unprecedented collaboration of leading plasma companies supported by global organizations outside...
-
Oct 1, 2020
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...
-
Sep 28, 2020HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older
KING OF PRUSSIA, PA – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication...
Sep 24, 2020The study narrowly missed statistical significance on the primary endpoint Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage The totality of...
-
Sep 18, 2020
Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435 In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of...
-
Sep 7, 2020
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...
-
Sep 4, 2020- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness
MARBURG, Germany 4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the...
-
Sep 1, 2020Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
St Gallen, September 1, 2020 – Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1,...
-
Aug 18, 2020
Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...
-
Aug 6, 2020
Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth...
-
Jul 30, 2020
Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...
-
Jul 30, 2020
Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...
Jul 30, 2020• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...
-
Jul 18, 2020
The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect. In...
-
Jul 16, 2020
Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...
-
Jul 13, 2020
Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...
-
Jul 9, 2020• Five coagulation researchers named this year’s recipients
KING OF PRUSSIA, Pa. – 9 July 2020 – Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Award for coagulation research just ahead of the...
-
Jul 6, 2020- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
KING OF PRUSSIA, Pa. – 6 July 2020 – Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy...
-
Jun 24, 2020• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
KING OF PRUSSIA, Pa., – 24 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an...
-
Jun 19, 2020
PHILADELPHIA--(June 19, 2020) – The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng,...
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020
This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
-
Jun 5, 2020
Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...
-
Jun 1, 2020
Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...
-
May 27, 2020Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.
WALTHAM, Mass. and KING OF PRUSSIA, Penn. 27 May 2020 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited...
-
May 26, 2020“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
Redmond, Wash., USA, and New York 26 May 2020 A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic...
-
May 18, 2020
ST GALLEN, CH and MOUNTAIN VIEW, Calif., 18 May, 2020 – Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six...
-
May 14, 2020
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Jacques Theurillat as new Chairman of the Board of Directors Etienne Jornod appointed...